



Commercial/Healthcare Exchange Step Criteria
Effective: February 17, 2021

Step Therapy Name: Reltone

Step 1 Agent(s): ursodiol capsule/tablet

Step 2 Agent(s): Reltone capsule

Medication/Class Description: Decreases the cholesterol content of bile and bile stones by reducing the secretion of cholesterol from the liver and the fractional reabsorption of cholesterol by the intestines. Mechanism of action in primary biliary cirrhosis is not clearly defined.

Required Medical Information:

1. Previous therapies tried and failed

Age Restrictions: N/A

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Exceptions for Stepped Medications

- A. Patient has had a trial and failure of a Step 1 Agent, defined as:
 - a. Failure to control/improve symptoms; **OR**
- B. Patient has intolerance to ONE Step 1 agent, defined as (but not limited to):
 - a. Allergic reaction
 - b. Adverse drug reactions

References:

1. Reltone (ursodiol) [prescribing information]. Las Vegas, NV: Intra-Sana Laboratories LLC; November 2020.

Policy Revision history

| Rev # | Type of Change | Summary of Change | Sections Affected | Date |
|-------|----------------|-------------------|-------------------|-----------|
| 1 | New Policy | New Policy | All | 2/17/2021 |

Last Res. February 2021



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

